Ribosomal protein L34 is a potential prognostic biomarker and therapeutic target in hilar cholangiocarcinoma

• Main Authors: Jianxin Qian, Lin Xu, Wenlong Yu, Xiaoqiang Gu, Yongjun Zuo, Ying Chen, Feng Xie, Lixin Wei
• Format: Article
• Language: English
• Published: BMC 2020-09-01
• Series: Cell & Bioscience
• Subjects: Ribosomal protein L34 (RPL34); Hilar cholangiocarcinoma; Tumor recurrence; Prognosis
• Online Access: http://link.springer.com/article/10.1186/s13578-020-00463-7
• ISSN: 2045-3701

Abstract Background Ribosomal protein 34 (RPL34) is a highly conserved protein belonging to the 60S large subunit of mammalian ribosomes that has been found to be dysregulated in a variety of human tumors. However, there are limited results that illuminate the role and expression profiles of RPL34 in hilar cholangiocarcinoma (HCCA). Methods RPL34 expression was detected in human HCCA by immunohistochemistry. The relationship of RPL34 expression with clinical outcomes was evaluated by univariate and multivariate analyses. The effect of RPL34 on cell migration and tumor growth was detected after silencing endogenous RPL34 expression. Results RPL34 was overexpressed in HCCA compared with normal tissue samples and correlated significantly with regional lymph node metastasis and poorly/undifferentiated tumors. Patients with high RPL34 expression had a shorter time to recur and a poorer outcome than those without RPL34 expression. Silencing RPL34 inhibited cell proliferation and migration in vitro and upregulated E-cadherin. Silencing RPL34 also attenuated tumor growth in vivo. Conclusions Our findings suggested that RPL34 might serve as a promising prognostic biomarker and a potential therapeutic target for the treatment of HCCA.